{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Pharmacological+Treatment&page=2", "query": { "intervention": "Pharmacological Treatment", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 13147, "total_pages": 1315, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Pharmacological+Treatment&page=3&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Pharmacological+Treatment&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-09T14:30:34.563Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00663767", "title": "A Study of ARRY-371797 in Subjects Undergoing Third Molar Extraction", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Dental Pain" ], "interventions": [ { "name": "Placebo; oral", "type": "DRUG" }, { "name": "ARRY-371797, p38 inhibitor; oral", "type": "DRUG" }, { "name": "Celecoxib, COX-2 inhibitor; oral", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 250, "start_date": "2008-04-07", "completion_date": "2008-06-20", "has_results": false, "last_update_posted_date": "2021-02-09", "last_synced_at": "2026-10-09T14:30:34.563Z", "location_count": 2, "location_summary": "Austin, Texas • Salt Lake City, Utah", "locations": [ { "city": "Austin", "state": "Texas" }, { "city": "Salt Lake City", "state": "Utah" } ], "official_url": "https://clinicaltrials.gov/study/NCT00663767" }, { "nct_id": "NCT03843671", "title": "Hyperbaric Radiation Sensitization of Head and Neck Cancers", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Squamous Cell Carcinoma of the Head and Neck" ], "interventions": [ { "name": "Hyperbaric oxygen", "type": "DRUG" }, { "name": "Hyperbaric chamber", "type": "DEVICE" } ], "intervention_types": [ "DRUG", "DEVICE" ], "sponsor": "National Baromedical Services", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 400, "start_date": "2019-07-01", "completion_date": "2024-12-31", "has_results": false, "last_update_posted_date": "2019-02-18", "last_synced_at": "2026-10-09T14:30:34.563Z", "location_count": 4, "location_summary": "Rochester, Minnesota • Lebanon, New Hampshire • Columbia, South Carolina + 1 more", "locations": [ { "city": "Rochester", "state": "Minnesota" }, { "city": "Lebanon", "state": "New Hampshire" }, { "city": "Columbia", "state": "South Carolina" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03843671" }, { "nct_id": "NCT04880434", "title": "Study of Brexucabtagene Autoleucel (KTE-X19) in Participants With Relapsed/Refractory Mantle Cell Lymphoma (Cohort 3)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Relapsed/Refractory Mantle Cell Lymphoma" ], "interventions": [ { "name": "Fludarabine", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Brexucabtagene autoleucel", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Kite, A Gilead Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 95, "start_date": "2021-04-23", "completion_date": "2025-06-17", "has_results": true, "last_update_posted_date": "2026-08-18", "last_synced_at": "2026-10-09T14:30:34.563Z", "location_count": 23, "location_summary": "Gilbert, Arizona • Palo Alto, California • Santa Monica, California + 19 more", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "Palo Alto", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04880434" }, { "nct_id": "NCT01319864", "title": "POETIC Plerixafor as a Chemosensitizing Agent for Relapsed Acute Leukemia and MDS in Pediatric Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Relapsed/Refractory AML", "Relapsed/Refractory ALL", "Secondary AML/MDS", "Acute Leukemia of Ambiguous Lineage", "AML", "ALL" ], "interventions": [ { "name": "Plerixafor Dose Escalation", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Seattle Children's Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "3 Years", "maximum_age": "29 Years", "sex": "ALL", "summary": "3 Years to 29 Years" }, "enrollment_count": 20, "start_date": "2011-03", "completion_date": "2016-06-28", "has_results": false, "last_update_posted_date": "2018-09-07", "last_synced_at": "2026-10-09T14:30:34.563Z", "location_count": 8, "location_summary": "Phoenix, Arizona • Denver, Colorado • Atlanta, Georgia + 5 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Denver", "state": "Colorado" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Kansas City", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT01319864" }, { "nct_id": "NCT02672098", "title": "Hyperthermic Intraperitoneal Chemotherapy for Recurrent Ovarian Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Ovarian Cancer" ], "interventions": [ { "name": "Hyperthermic intraperitoneal chemotherapy (HIPEC)", "type": "PROCEDURE" }, { "name": "Carboplatin", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "DRUG" ], "sponsor": "Loma Linda University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "21 Years", "maximum_age": null, "sex": "ALL", "summary": "21 Years and older" }, "enrollment_count": 3, "start_date": "2016-07-14", "completion_date": "2023-04-19", "has_results": false, "last_update_posted_date": "2025-05-22", "last_synced_at": "2026-10-09T14:30:34.563Z", "location_count": 1, "location_summary": "Loma Linda, California", "locations": [ { "city": "Loma Linda", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02672098" }, { "nct_id": "NCT04310007", "title": "Testing the Addition of the Pill Chemotherapy, Cabozantinib, to the Standard Immune Therapy Nivolumab Compared to Standard Chemotherapy for Non-small Cell Lung Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Lung Non-Squamous Non-Small Cell Carcinoma", "Recurrent Lung Non-Squamous Non-Small Cell Carcinoma", "Stage IV Lung Cancer AJCC v8" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Cabozantinib S-malate", "type": "DRUG" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Docetaxel", "type": "DRUG" }, { "name": "Echocardiography Test", "type": "PROCEDURE" }, { "name": "Gemcitabine Hydrochloride", "type": "DRUG" }, { "name": "Nab-paclitaxel", "type": "DRUG" }, { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Ramucirumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "PROCEDURE", "DRUG", "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 117, "start_date": "2020-07-13", "completion_date": "2027-03-31", "has_results": false, "last_update_posted_date": "2026-09-29", "last_synced_at": "2026-10-09T14:30:34.563Z", "location_count": 611, "location_summary": "Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 392 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" } ], "official_url": "https://clinicaltrials.gov/study/NCT04310007" }, { "nct_id": "NCT01811992", "title": "Combined Cytotoxic and Immune-Stimulatory Therapy for Glioma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Malignant Glioma", "Glioblastoma Multiforme" ], "interventions": [ { "name": "Dose Escalation of Ad-hCMV-TK and Ad-hCMV-Flt3L", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "University of Michigan Rogel Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 19, "start_date": "2014-04", "completion_date": "2021-01", "has_results": false, "last_update_posted_date": "2024-09-19", "last_synced_at": "2026-10-09T14:30:34.563Z", "location_count": 1, "location_summary": "Ann Arbor, Michigan", "locations": [ { "city": "Ann Arbor", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT01811992" }, { "nct_id": "NCT00440011", "title": "Bimatoprost 0.03% Versus Travoprost 0.004% in Patients Currently on Latanoprost 0.005%", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Glaucoma", "Ocular Hypertension" ], "interventions": [ { "name": "bimatoprost 0.03% eye drops", "type": "DRUG" }, { "name": "travoprost 0.004% eye drops", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Allergan", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 266, "start_date": "2006-08", "completion_date": "2007-10", "has_results": true, "last_update_posted_date": "2019-04-25", "last_synced_at": "2026-10-09T14:30:34.563Z", "location_count": 1, "location_summary": "San Diego, California", "locations": [ { "city": "San Diego", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00440011" }, { "nct_id": "NCT00360971", "title": "Palifermin in Lessening Oral Mucositis in Patients Undergoing Radiation Therapy and Chemotherapy for Locally Advanced Head and Neck Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Head and Neck Cancer", "Mucositis", "Pain", "Radiation Toxicity" ], "interventions": [ { "name": "palifermin", "type": "BIOLOGICAL" }, { "name": "cisplatin", "type": "DRUG" }, { "name": "placebo", "type": "OTHER" }, { "name": "neck dissection", "type": "PROCEDURE" }, { "name": "radiation therapy", "type": "RADIATION" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "OTHER", "PROCEDURE", "RADIATION" ], "sponsor": "Radiation Therapy Oncology Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 21, "start_date": "2006-07", "completion_date": "2009-02", "has_results": true, "last_update_posted_date": "2017-12-26", "last_synced_at": "2026-10-09T14:30:34.563Z", "location_count": 47, "location_summary": "Scottsdale, Arizona • Auburn, California • Burbank, California + 40 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Auburn", "state": "California" }, { "city": "Burbank", "state": "California" }, { "city": "Cameron Park", "state": "California" }, { "city": "Carmichael", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00360971" }, { "nct_id": "NCT00002463", "title": "Combination Chemotherapy in Treating Children With Astrocytomas and Primitive Neuroectodermal Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Brain and Central Nervous System Tumors" ], "interventions": [ { "name": "MOPP Regimen", "type": "DRUG" }, { "name": "Leucovorin Calcium", "type": "DRUG" }, { "name": "Mechlorethamine Hydrochloride", "type": "DRUG" }, { "name": "Methotrexate", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Procarbazine Hydrochloride", "type": "DRUG" }, { "name": "Vincristine Sulfate", "type": "DRUG" }, { "name": "Conventional Surgery", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "3 Years", "sex": "ALL", "summary": "Up to 3 Years" }, "enrollment_count": 4, "start_date": "1989-02", "completion_date": "2008-01", "has_results": false, "last_update_posted_date": "2013-02-18", "last_synced_at": "2026-10-09T14:30:34.563Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00002463" } ] }